p27(kip1) and other cell-cyde protein expression in normal and neoplastic endocrine tissues

Endocrine Pathology

Volumn 11, Issue 2, 2000, Pages 109-122

  Erickson, Lori A ^a,b  

^a MAYO CLINIC   (United States)

^b Dept of Lab Medicine and Pathology ^*  (United States)

Author keywords

Adrenal; Cell cycle; Endocrine; p27kip1; Parathyroid; Pituitary; Thyroid

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; PROTEIN P15; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53;

BREAST TUMOR; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; ENDOCRINE TUMOR; EPITHELIUM TUMOR; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS ADENOMA; NEUROBLASTOMA; NONHUMAN; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE TUMOR; PROTEIN EXPRESSION; REVIEW; THYROID FOLLICULAR CARCINOMA;

EID: 0033854492     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/EP:11:2:109     Document Type: Review

References (91)

1. 1. Schantz A, Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer 31:600-605, 1973.
2. 2. Abbona GC, Papotti M, Gasparri G, Bussolati G. Proliferative activity in parathyroid tumors as detected by Ki67 immunostaining. Hum Pathol 26:135-138, 1995.
3. 3. Katoh R, Bray CE, Suzuki K, Komiyama A, Hemmi A, Kawoi A, Oyama T, Sugai T, Sasau S. Growth activity in hyperplastic and neoplastic human thyroid determined by an immunohistochemical staining procedure using monoclonal antibody MIB-1. Hum Pathol 26:139-146, 1995.
4. 4. Kitz K, Knosp E, Koos WT, Korn A. Proliferation of pituitary adenomas: measurement by MAb Ki-67. Acta Neurochiurg Suppl (Wien) 53:60-64, 1991.
5. 5. Goldblum JR, Shannon R, Keldjian EP, Thiny M, Davenport R, Thompson N, Lloyd RV. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Modern Pathol 6:663-668, 1993.
6. 6. Pelosi G, Zamboni G, Doglioni D, Rodella S, Bresaola E, Iacono C, Serio G, Iannucci A, Scarpa A. Immunodetection of proliferating cell nuclear antigen assesses growth fraction and predicts malignancy in endocrine tumors of the pancreas. Am J Surg Pathol 16:1215-1225, 1992.
7. 7. Kovacs K, Asa SL. Functional endocrine pathology. Malden, MA: Blackwell Science, 1988.
8. 8. Sherr CJ. G1 phase progression: cycling on cue. Cell 79:551-555, 1994.
9. 9. Hunter T, Pines J. Cyclins and cancer II: cyclin D and inhibitors come of age. Cell 79:573-582, 1994.
10. 10. Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, Matthew S, Krauter K, Sheinfeld J, Massague J, Cordon-Cardo C. p27kip1 chromosomal mapping to 12p 12-12p13.1 and absence of mutations in human tumors. Cancer Res 55:1211-1214, 1995.
11. 11. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. Cloning of p27kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66, 1994.
12. 12. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993.
13. 13. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ. p57/kip2, a structurally distinct member of the p21/CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650-662, 1995.
14. 14. Sherr CJ. Cancer cell cycles. Science 274:1672-1677, 1996.
15. 15. Kato JY, Matsuoka M, Polyak K, Massague J, Sherr CJ. Cyclin AMP-induced G1 phase arrest mediated by an inhibitor (p27kip1) of cyclin-dependent kinase 4 activation. Cell 79:487-496, 1994.
16. 16. Dahia PL, Aguiar RC, Honegger J, Fahlbush R, Jordan S, Lowe DG, Lu X, Clayton RN, Besser GM, Grossman AB. Mutation and expression analysis of the p27kip1 gene in corticotropin-secreting tumors. Oncogene 16:69-76, 1998.
17. 17. Ikeda H, Yoshimoto T, Shida N. Molecular analysis of p21 and p27 genes in human pituitary adenomas. Br. J. Cancer 76:1119-1123, 1997.
18. 18. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K. Mice lacking p27kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720, 1996.
19. 19. Fero ML, Rande IE, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27kip1 is haplo-insufficient for tumour suppression. Nature 396:177-180, 1998.
20. 20. Elisei R, Shiohara M, Koeffler HP, Fagin JA. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p1 5INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer 83:2185-2193, 1998.
21. 21. Zedenius J, Larsson C, Wallin G, Backdahl M, Aspenblad U, Hoog A, Borresen AL, Auer G. Alterations of p53 and expression of WAF1/p21 in human thyroid tumors. Thyroid 6:1-9, 1996.
22. 22. Pagano M, Tam SW, Theodoras AM, Romero-Beer P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685, 1995.
23. 23. Hengst L, Reed SI. Translational control of p27kip1 accumulation during the cell cycle. Science 271:1861-1864, 1996.
24. 24. Qian X, Jin L, Grande JP, Lloyd RV. Transforming growth factor-B and p27 expression in pituitary cells. Endocrinology 137:3051-3060, 1996.
25. 25. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27kip1. Genes Dev 11:1464-1478, 1997.
26. 26. Pagano M, Tam SW, Theodoras AM, Romero-Beer P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. Role of the ubiquitin-proceasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685, 1995.
27. 27. Qian X, Jin L, Kulig E, Lloyd RV. DNA methylation regulates p27kip1 expression in rodent pituitary cell lines. Am J Pathol 153:1475-1482, 1998.
28. 28. Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B. Growth arrest by the cyclin-dependent kinase inhibitor p27kip1 is abrogated by c-Myc. EMBO J 15:6595-6604, 1996.
29. 29. Cheng M, Sexl V, Sherr CJ, Roussel MF. Assembly of cyclin D-dependent kinase and titration of p27kip1 regulated by mitogen-activated protein kinase (MEK1). Proc Natl Acad Sci USA 95:1091-1096, 1998.
30. 30. Kaplan MH, Daniel C, Schindler U, Grusby MJ. Stat protein control lymphocyte proliferation by regulating p27kip1 expression. Mol Cell Biol 18:1996-2003, 1998.
31. 31. Katayose Y, Kim M, Rakkar ANS, Li Z, Cowan KH, Seth P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 57:5441-5445, 1997.
32. 32. Perez-Juste G, Aranda A. The cyclin-dependent kinase inhibitor p27(Kip1) is involved in thyroid hormone-mediated neuronal differentiation. J Biol Chem 274:5026-5031, 1999.
33. 33. St Croix B, Florens VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS. Impact of the cyclin-dependent kinase inhibitor p27kip1 on resistance of tumor cells to anticancer agents. Nat Med 2:1204-1210, 1996.
34. 34. Ophascharoensuk V, Fero ML, Hughes J, Roberts JM, Shankland SJ. The cyclin-dependent kinase inhibitor p27kip1 safeguards against inflammatory injury. Nat Med 4:575-580, 1998.
35. 35. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ, Lu X. High level expression of p27kip1 and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94:6380-6385, 1997.
36. 36. Porter PL., Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM. Expression of cell-cycle regulators p27kip1 and cyclin E, alone and in combination, correlates with survival in young breast cancer patients. Nat Med 3:222-225, 1997.
37. 37. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Marava-Protzner I, Kapuska L, Fransen E, Pritchard KI, Slingerland JM. Decreased levels of the cell-cycle inhibitor p27kip1 protein: prognostic implications in primary breast cancer. Nat Med 3:227-230, 1997.
38. 38. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1ab) invasive breast carcinoma. Cancer Res 57:1259-1263, 1997.
39. 39. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinoma. Nat Med 3:231-234, 1997.
40. 40. Ciaparrone M, Yamamoto H, Yao Y, Sgambato A, Cattoretti G, Tomita N, Monden T, Rotterdam H, Weinstein IB. Localization and expression of p27kip1 in multistage colorectal carcinogenesis. Cancer Res 58:114-122, 1998.
41. 41. Singh SP, Lipman J, Goldman H, Ellis FH, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 58:1730-1735, 1998.
42. 42. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Susimachi K, Akiyoshi T. p27 expression and gastric carcinoma. Nat Med 3:593, 1997.
43. 43. Esposito V, Baldi A, DeLuca A, Groger AM, Loda M, Giordano GG, Gaputi M, Baldi F, Pagano M, Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Caner Res 57:3381-3385, 1997.
44. 44. Kawana H, Tamaru J, Tanaka T, Hirai A, Saito Y, Kitagawa M, Mikata A, Harigaya K, Kuriyama T. Role of p27kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. Am J Pathol 153:505-513, 1998.
45. 45. Yatabe Y, Masuda A, Koshikowa T, Nakamura S, Kuroishi T, Osada H, Takahashi T, Mitsudomi T, Takahashi T. p27kip1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res 58:1042-1047, 1998.
46. 46. Tsihlias J, Kapusta LR, DeBuer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM. Loss of cyclin-dependent kinase inhibitor p27kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58:542-548, 1998.
47. 47. Yang RM, Naitoh HJ, Murphy M, Wang HJ, Phillipson J, DeKernion JB, Loda M, Reiter RE. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159:941-945, 1998.
48. 48. Cheville JC, Lloyd RV, Sebo TJ, Cheng L, Erickson L, Bostwick DG, Lohse CM, Wollan P. Expression of p27kip1 in prostatic adenocarcinoma. Modern Pathol 11:324-328, 1998.
49. 49. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, Scher HI. Distinct altered patterns of p27kip1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 90:1284-1291, 1998.
50. 50. Sanchez-Beato M, Saez AI, Martinez-Montero JC, Sol Mateo M, Sanchez-Verde L, Villuendas R, Troncone G, Piris MA. Cyclin-dependent kinase inhibitor p27kip1 in lymphoid tissue: p27kip1 expression is inversely proportional to the proliferative index. Am J Pathol 151:151-160, 1997.
51. 51. Quintanilla-Martinez L, Thieblemant C, Fend F, Kumar S, Pinyal M, Campo E, Jaffe ES, Raffeld M. Mantle cell lymphomas lack expression of p27kip1, a cyclin-dependent kinase inhibitor. Am J Pathol 153:175-182, 1998.
52. 52. Lloyd RV, Jin L, Qian X, Kulig E. Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol 150:401-407, 1997.
53. 53. Erickson LA, Jin L, Wollan PC,Thompson GB, van Heerden J, Lloyd RV. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Modern Pathol 11:169-174, 1998.
54. 54. Resnick MB, Schacter P, Finkelstein Y, Kellner Y, Cohen O. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. Modern Pathol 11:735-739, 1998.
55. 55. Wang S, Wuu J, Savas L, Patwardhan N, Khan A. The role of cell cycle regulatory proteins, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis. Hum Pathol 29:1304-1309, 1998.
56. 56. Lloyd RV, Ferrero JA, Jin L, Sebo T, TGF-B, TGF-B receptors: Ki-67 and p27kip1 expression in papillary thyroid carcinomas. Endocr Pathol 4:293-300, 1997.
57. 57. Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S, Carcangiu ML. Downregulation of p27KIPI and KI67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol 23:678-685, 1999.
58. 58. Okayasu I, Osakabe T, Onozawa M, Mikami T, Fujiwara M. p53 and p21 (WAF1) expression in lymphocytic thyroiditis and thyroid tumors. Clin Immunol Immunopathol 88: 183-191, 1998.
59. 59. Shi Y, Zou M, Farid NR, al-Sedairy ST. Evidence of gene deletion of p21 (WAF1/ CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas. Br J Cancer 74:1336-1341, 1996.
60. 60. Zou M, Shi Y, Farid NR, Al-Sedairy ST. Inverse association between cyclin D1 overexpression and retinoblastoma gene mutation in thyroid carcinomas. Endocrine 8:61-64, 1998.
61. 61. Lazzereschi D, Sambuco L, Scalzo CC, Ranieri AR, Mincione G, Nardi F, Colletta G. Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int J Cancer 76:806-811, 1998.
62. 62. Erickson LA, Jin L, Goellner JR, Lohse C, Pankratz VS, Zukerberg LR, Thompson GB, van Heerden JA, Grant CS, Lloyd RV. Pathologic features, proliferative activity and cyclin D1 expression in Hurthle cell neoplasms of the thyroid. Modern Pathol, 13:186-192, 2000.
63. 63. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, Arnold A. A novel cyclin encoded by a bcl-linked candidate oncogene. Nature 350:512-515, 1991.
64. 64. Withers DA, Harvey RC, Faust JB, Melnyk O, Carey K, Meeker TC. Characterization of a candidate bcl-1 gene. Mol Cell Biol 11:4846-4853, 1991.
65. 65. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL. Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133, 1993.
66. 66. Jiang W, Kahn SM, Tomira N, Zhang YJ, Lu SH, Weinstein IB. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 52:2980-2983, 1992.
67. 67. Horenstein MG, Cesarman E, Wang X, Linkov I, Prieto VG, Louie CD. Cyclin D1 and retino-blastoma protein expression in Kaposi's sarcoma. J Cutan Pathol 24:585-589, 1997.
68. 68. Sutter T, Doi S, Carnevale KA, Arber N, Weinstein IB. Expression of cyclins D1 and E in human colon adenocarcinomas. J Med 28:285-309, 1997.
69. 69. Ran EK, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 35:95-101, 1998.
70. 70. Proctor AJ, Coombs LM, Cairns JP, Knowles MA. Amplification at chromosome 11q13 in transitional cell tumors of the bladder. Oncogene 6:789-795, 1991.
71. 71. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 55:975-978, 1995.
72. 72. Muro-Cacho CA, Munoz-Antonia T, Livingston S, Klotch D. Transforming growth factor beta receptors and p27kip1 in thyroid carcinoma. Arch Otolaryngol Head Neck Surg 125:76-81, 1999.
73. 73. Muro-Cacho CA, Holt T, Klotch D, Mora L, Livingston S, Futran N. Cyclin D1 expression as a prognostic parameter in papillary carcinoma of the thyroid. Otolaryngol Head Neck Surg 120:200-207, 1999.
74. 74. Jin L, Qian X, Kulig E, Sanno N, Scheithauer BW, Kovacs K, Young WF Jr, Lloyd RV Transforming growth factor-B, transforming growth factor-B receptor II, and p27kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 151:509-519, 1997.
75. 75. Zhao D, Tomono Y, Nose T. Expression of p27kip1 and Ki-67 in pituitary adenomas: an investigation of marker of adenoma invasiveness. Acta Neurochir (Wien) 141:187-192, 1999.
76. 76. Takeuchi S, Koeffler HP, Hinton DR, Miyoshi I, Melmed S, Shimon I. Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors. J Endocrinol 157:337-341, 1998.
77. 77. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L, Xiong Y. CDK inhibitors p18INK4c and p27kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12:2899-2911, 1998.
78. 78. Woloschak M, Yu A, Xiao J, Post KD. Frequent loss of the p16INK4a gene product in human pituitary tumors. Cancer Res 56:2493-2496, 1996.
79. 79. Woloschak M, Yu A, Post KD. Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation. Mol Carcinog 19:221-224, 1997.
80. 80. Castleman B, Roth SI. Tumors of the parathyroid glands. Atlas of tumor pathology, 2nd series, fascicle 14. Washington, DC: Armed Forces Institute of Pathology, 1978.
81. 81. DeLellis RA. Tumors of the parathyroid glands. Atlas of tumor pathology, 3rd series, fascicle 6. Washington, DC: Armed Forces Institute of Pathology, 1993.
82. 82. Erickson LA, Jin L, Wollan P, Thompson GB, van Heerden JA, Lloyd RV. Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. Am J Surg Pathol 23:288-295, 1999.
83. 83. Hsi ED, Zukerberg LR, Yang W-I, Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas. J Clin Endocrinol Metab 81:1736-1739, 1996.
84. 84. Friedman E, Bale AE, Marx SJ, Norton JA, Arnold A, Tu T, Aurbach CD, Spiegel AM. Genetic abnormalities in sporadic parathyroid adenomas. J Clin Endocrinol Metab 71:293-297, 1990.
85. 85. Arnold A, Staunton CE, Kim HG, Gaz RD, Kronenberg HM. Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. N Engl J Med 318:658-662, 1988.
86. 86. Arnold A, Kim HG, Gaz RD, Eddy RL, Fukushima Y, Byers MG, Shows TB, Kronenberg HM. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 83:2034-2040, 1989.
87. 87. Nakazumi H, Sasano H, Iino K, Ohashi Y, Orikasa S, Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. Modern Pathol 11:1165-1170, 1998.
88. 88. Iida S, Fujii H, Moriwaki K. A somatic mutation of the p21(Waf1/Cip1) gene in a human adrenocortical adenoma. Anticancer Res 17:633-636, 1997.
89. 89. Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, Depinho RA, Elledge SJ. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 387:151-158, 1997.
90. 90. Liu J, Kahri AI, Heikkila R Voutilainen R. Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-like growth factor II, and H19, in adrenal tumors and cultured adrenal cells. J Clin Endocrinol Metab 82:1766-1771, 1997.
91. 91. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154:313-323, 1999.